Emerging Molecules
Semaglutide is one molecule and at least two evidence files
SELECT used 2.4 mg weekly in people without diabetes. FLOW used 1 mg weekly in people with type 2 diabetes and chronic kidney disease. The files do not merge.
Semaglutide is a GLP-1 receptor agonist. That chemical fact is not a single clinical result. SELECT randomized weekly semaglutide 2.4 mg in adults with cardiovascular disease and overweight or obesity who did not have diabetes, and followed a cardiovascular composite. FLOW randomized weekly semaglutide 1.0 mg in adults with type 2 diabetes and chronic kidney disease, and followed a kidney composite.
What does not carry across
A 0.80 hazard ratio from SELECT is not FLOW’s 0.76 hazard ratio written a second time. The doses differ. The diseases required for entry differ. The primary events differ. Someone quoting “semaglutide works for the heart and the kidney” has collapsed two trials into a slogan. Each hazard ratio stays with its own paper.
Why this is still an emerging reading
The molecule is approved for specified uses, at specified doses, on specified labels. New trials keep adding populations. Until a label names the population, the trial is the evidence, and the next trial is a different evidence file. Neither file describes a research-supply powder.